| Literature DB >> 31481077 |
Masafumi Maseda1, Hiroshi Uei2,3, Masahiro Nakahashi1, Hirokatsu Sawada1, Yasuaki Tokuhashi1.
Abstract
BACKGROUND: Therapeutic intervention has recently been actively performed for metastatic spine tumor even though spinal cord paralysis is not clearly observed, but there has been no report in which the degree of spinal cord compression by tumor was taken into consideration for the paralysis-preventing effect of treatment. Thus, we investigated the neurological outcome after treatment of patients with spinal cord compression in a state of impending paralysis.Entities:
Keywords: Epidural spinal cord compression; Metastatic spine tumor; Paralysis; Radiotherapy; Surgery
Mesh:
Year: 2019 PMID: 31481077 PMCID: PMC6724255 DOI: 10.1186/s13018-019-1348-x
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Fig. 1Epidural spinal cord compression (ESCC) scale [8]
Demographic and pre-treatment data according to the treatments employed
| Type of treatment | Posterior stabilization with decompression ( | Posterior stabilization without decompression ( | Radiotherapy ( |
|---|---|---|---|
| Male vs. female | 12:6 | 9:6 | 40:15 |
| Age (years), mean | 39–83, 62.5 ± 11.8 | 40–82, 63.1 ± 13.9 | 36–85, 65.5 ± 11.5 |
| The level of the spine that exhibited the greatest tumor-related spinal cord compression | |||
| C1-T2 level | 5 | 3 | 9 |
| T3-L1 level | 6 | 4 | 22 |
| L2-S1 level | 7 | 8 | 24 |
| No. of affected vertebral body, mean | 1–4, 2.1 ± 1.1 | 1–12, 3.5 ± 3.4 | 1–9, 3.3 ± 2.2 |
| Primary site | |||
| Lung | 6 | 5 | 31 |
| Kidney | 3 | 1 | 2 |
| Prostate | 1 | 1 | 4 |
| Liver | 3 | 3 | 6 |
| Breast | 1 | 3 | 0 |
| Others | 4 | 2 | 12 |
| No. of VAS 0 | 0 (0%) | 0 (0%) | 6 (10.9%) |
| Transverse location | |||
| A | 3 | 5 | 23 |
| AP | 2 | 2 | 15 |
| AF | 9 | 6 | 6 |
| APF | 4 | 2 | 11 |
| ESCC scale | |||
| 1b | 9 | 7 | 28 |
| 1c | 5 | 5 | 19 |
| 2 | 2 | 3 | 7 |
| 3 | 2 | 0 | 1 |
| Spinal instability neoplastic score | 10.1 ± 2.4 | 10.5 ± 2.5 | 9.3 ± 2.4 |
| Additional adjuvant therapy | Radiotherapy 8, chemotherapy 11, BMA 3, no 2 | Radiotherapy 11, chemotherapy 9, BMA 2, no. 1 | Chemotherapy 20, BMA 17, no. 17 |
| Survival period (months), mean | 1–116, 16.0 ± 28.0 | 2–14, 7.2 ± 3.9 | 0.3–34, 7.7 ± 7.5 |
| Pre-treatment Barthel index, mean | 49–100, 81.5 ± 20.7 | 70–85, 77.5 ± 10.6 | 10–100, 68.0 ± 30.6 |
VAS visual analog scale score, A anterior lesion, AP anterior + posterior lesion, AF anterior + foraminal lesion, APF anterior + posterior + foraminal lesion, ESCC epidural spinal cord compression, BMA bone-modifying agent
Fig. 2Transverse localization of tumors [10]
Fig. 3Incidence of paralysis by treatment method
Fig. 4Incidence of paralysis by localization in transverse view
Fig. 5Incidence of paralysis by ESCC scale
Factor influencing neurological outcomes
| Factor | Parameter | |
|---|---|---|
| Type of treatment | PSD 3 (16.7%), PS 2 (13.3%), Rad 10 (18.8%) | 0.9642 |
| Male vs. female | 9/61 (14.8%) vs. 6/27 (22.2%) | 0.3902 |
| Age (years), mean | 39–85, 64.4 ± 12.6 | 0.9956 |
| The level of the spine that exhibited the greatest tumor-related spinal cord compression | C1-T2 level 2 (11.8%), T3-L1 level 8 (25.0%), L2-S1 level 5 (12.8%) | 0.3539 |
| No. of affected vertebral body, mean | 1–8, 3.4 ± 2.3 | 0.5415 |
| Primary site | Lung 7, kidney 3, colon 1, unknown 3, others 1 | 0.6713 |
| No. of VAS 0 | 2 (13.3%) | 0.2717 |
| Transverse location | A 6 (13.3%), AP 3 (15.8%), AF 5 (23.8%), APF 3 (60%) | 0.9316 |
| ESCC scale | 1b 5 (11.3%), 1c 6 (20.7%), 2 3 (25%), 3 1 (33.3%) | 0.1325 |
| Spinal instability neoplastic score | 10.5 ± 8.6 (vs. 9.5 ± 5.4) | 0.2287 |
| Additional adjuvant therapy | No 6/26 (23.1%) | 0.3299 |
| Survival period (months), mean | 1.5–20, 7.7 ± 6.0 | 0.4296 |
| Pre-treatment Barthel index, mean | 40–100, 89.3 ± 22.4 | 0.0666 |
PSD posterior stabilization with decompression, PS posterior stabilization without decompression, VAS visual analog scale score, A anterior lesion, AP anterior + posterior lesion, AF anterior + foraminal lesion, APF anterior + posterior + foraminal lesion, ESCC epidural spinal cord compression, No no additional adjuvant therapy